Liquid Biopsy Based Minimal Residual Disease Testing Market

According to Stratistics MRC, the Global Liquid Biopsy-Based Minimal Residual Disease Testing Market is accounted for $2.4 billion in 2026 and is expected to reach $9.8 billion by 2034 growing at a CAGR of 19.2% during the forecast period. Liquid Biopsy-Based Minimal Residual Disease Testing utilizes circulating tumor DNA, advanced molecular diagnostics, and high-sensitivity sequencing technologies to detect residual cancer cells and monitor recurrence risks. Increasing cancer prevalence, growing demand for personalized oncology, and rising adoption of non-invasive diagnostic technologies are driving market growth. Technological advancements in next-generation sequencing, digital PCR, and tumor-informed assays are improving detection capabilities. Growing investment in precision oncology, adjuvant therapy optimization, and clinical trial monitoring is creating opportunities across diagnostic laboratories, healthcare providers, and biotechnology companies.

Market Dynamics:

Driver:

Increasing cancer prevalence and demand for early recurrence detection

Increasing cancer prevalence and demand for early recurrence detection are driving adoption of liquid biopsy-based minimal residual disease testing. Healthcare providers increasingly utilize circulating tumor DNA analysis to identify molecular evidence of residual cancer following treatment. These tests support recurrence risk assessment, treatment monitoring, and personalized oncology decisions. Growing adoption of precision medicine, expanding cancer survivorship populations, and increasing clinical evidence encourage utilization. Advances in high-sensitivity sequencing and molecular diagnostic technologies further strengthen market development.

Restraint:

High testing costs and limited standardization of clinical validation

High testing costs and limited standardization of clinical validation restrain adoption of liquid biopsy-based MRD testing. Advanced molecular assays require sophisticated sequencing infrastructure, specialized laboratory expertise, and complex bioinformatics analysis. Differences in assay sensitivity, biomarker selection, and testing protocols complicate clinical interpretation. Reimbursement uncertainty and limited evidence supporting treatment decisions in certain cancers create additional barriers. Healthcare providers may hesitate to implement routine testing without established clinical guidelines and demonstrated improvements in patient outcomes.

Opportunity:

Expansion of personalized oncology and ctDNA-guided treatment decisions

Expansion of personalized oncology and ctDNA-guided treatment decisions presents significant growth opportunities. Advanced liquid biopsy assays enable molecular assessment of residual disease, recurrence risk, and treatment response through minimally invasive blood sampling. Integration with precision oncology programs supports risk-adapted surveillance and investigation of personalized adjuvant therapies. Pharmaceutical companies increasingly incorporate MRD endpoints into clinical trials to evaluate therapeutic effectiveness. Growing investment in high-sensitivity sequencing, biomarker discovery, and clinical validation encourages innovation and commercialization.

Threat:

False-negative results and competition from conventional cancer surveillance methods

False-negative results and competition from conventional cancer surveillance methods pose significant challenges to liquid biopsy-based MRD testing. Low circulating tumor DNA concentrations, biological variability, and differences in tumor shedding can affect detection sensitivity. Inaccurate results may influence clinical decisions and patient confidence. Conventional imaging, tissue biopsy, and established surveillance protocols remain important alternatives. Increasing regulatory scrutiny, evolving reimbursement requirements, and demands for robust clinical evidence compel manufacturers to demonstrate reliable assay performance and clinical utility.

Covid-19 Impact:

The COVID-19 pandemic increased interest in minimally invasive cancer diagnostics and remote-compatible monitoring approaches. Healthcare organizations explored blood-based molecular testing to reduce certain hospital visits and support oncology surveillance. However, disruptions to diagnostic services, clinical trials, and laboratory operations affected testing volumes and research activities. Supply chain constraints also influenced molecular diagnostic workflows. Subsequent recovery in cancer screening, expanding precision oncology programs, and growing investment in liquid biopsy technologies continue to support market development.

The circulating tumor DNA (ctDNA) segment is expected to be the largest during the forecast period

The circulating tumor DNA (ctDNA) segment is expected to account for the largest market share during the forecast period due to widespread development of highly sensitive molecular residual disease assays. ctDNA testing enables detection of tumor-associated genetic alterations in blood samples following cancer treatment. Growing clinical evidence supporting molecular recurrence monitoring, increasing adoption of personalized oncology, and expanding sequencing capabilities encourage utilization. Advances in tumor-informed assay design, deep sequencing, and molecular error correction strengthen detection performance and commercialization.

The multimodal liquid biopsy biomarkers segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the multimodal liquid biopsy biomarkers segment is predicted to witness the highest growth rate due to increasing demand for improved residual disease detection sensitivity. These approaches combine circulating tumor DNA with complementary molecular or cellular indicators to characterize cancer persistence and recurrence risks. Advances in integrated sequencing, methylation analysis, and computational analytics are improving research capabilities. Growing investment in comprehensive liquid biopsy platforms and precision oncology is expected to accelerate clinical development and adoption.

Region with largest share:

During the forecast period, North America is expected to hold the largest share due to advanced oncology infrastructure, substantial investment in molecular diagnostics, and increasing adoption of precision medicine. The United States leads regional development through diagnostic laboratories, biotechnology companies, and cancer research institutions developing liquid biopsy-based MRD assays. Established clinical trial networks, expanding oncology testing programs, and growing demand for recurrence monitoring encourage adoption. Investment in sequencing technologies and partnerships between diagnostic developers and healthcare providers strengthen commercialization.

Region with highest CAGR:

Over the forecast period, Asia Pacific is anticipated to exhibit the highest CAGR, supported by expanding oncology infrastructure, increasing cancer prevalence, and growing investment in molecular diagnostic technologies. China, Japan, India, South Korea, and Australia are advancing precision oncology programs and liquid biopsy research. Improving access to genomic testing, increasing clinical research activity, and growing demand for personalized cancer management encourage adoption. Government healthcare initiatives and collaborations between diagnostic developers and research institutions support regional growth.

Key players in the market

Some of the key players in the Liquid Biopsy-Based Minimal Residual Disease Testing Market include Natera, Inc., Guardant Health, Inc., Foundation Medicine, Inc., Personalis, Inc., Exact Sciences Corporation, Quest Diagnostics Incorporated, NeoGenomics Laboratories, Inc., Foresight Diagnostics, Inc., Myriad Genetics, Inc., Tempus AI, Inc., Caris Life Sciences, Inc., Predicine, Inc., Naveris, Inc., Adaptive Biotechnologies Corporation, Veracyte, Inc., Burning Rock Biotech Limited, Genetron Health, and F. Hoffmann-La Roche Ltd.

Key Developments:

In October 2026, Personalis, Inc. announced the commercial launch of Real-Time Variant Tracker supplemental results within its NeXT Personal molecular residual disease testing platform. The capability enables monitoring of clinically relevant resistance mutations and therapeutically targetable variants during cancer surveillance, expanding the clinical information available through ultrasensitive ctDNA analysis.

In October 2026, Natera, Inc. announced new clinical evidence supporting its Signatera molecular residual disease testing technologies at the European Society for Medical Oncology Congress. The presentations highlighted ultrasensitive ctDNA detection, treatment response assessment, and recurrence monitoring across multiple cancer types, strengthening the evidence base for personalized oncology management.

In October 2026, Guardant Health, Inc. announced publication of the COSMOS study in Cancer Research Communications, demonstrating the clinical utility of its Guardant Reveal liquid biopsy test for predicting melanoma recurrence. The findings support expanded applications of blood-based molecular residual disease testing in cancer surveillance and risk assessment.

Biomarker Types Covered:
• Circulating Tumor DNA (ctDNA)
• Circulating Tumor Cells (CTCs)
• Circulating Tumor RNA (ctRNA)
• Multimodal Liquid Biopsy Biomarkers
• Other Biomarker Types

Testing Approaches Covered:
• Tumor-Informed MRD Testing
• Tumor-Naive MRD Testing
• Hybrid MRD Testing Approaches
• Other Testing Approaches

Technologies Covered:
• Next-Generation Sequencing (NGS)
• Digital Polymerase Chain Reaction (dPCR)
• Quantitative Polymerase Chain Reaction (qPCR)
• Methylation-Based Molecular Analysis
• Circulating Tumor Cell Detection Technologies
• Other Technologies

Cancer Types Covered:
• Colorectal Cancer
• Breast Cancer
• Lung Cancer
• Bladder Cancer
• Prostate Cancer
• Head & Neck Cancer
• Hematological Malignancies
• Other Cancer Types

Applications Covered:
• Post-Surgical Residual Disease Detection
• Cancer Recurrence Surveillance
• Treatment Response Monitoring
• Adjuvant Therapy Decision Support
• Cancer Relapse Risk Stratification
• Clinical Trial Patient Selection & Monitoring
• Other Applications

Regions Covered:
• North America
o United States
o Canada
o Mexico
• Europe
o United Kingdom
o Germany
o France
o Italy
o Spain
o Netherlands
o Belgium
o Sweden
o Switzerland
o Poland
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o South Korea
o Australia
o Indonesia
o Thailand
o Malaysia
o Singapore
o Vietnam
o Rest of Asia Pacific
• South America
o Brazil
o Argentina
o Colombia
o Chile
o Peru
o Rest of South America
• Rest of the World (RoW)
o Middle East
 Saudi Arabia
 United Arab Emirates
 Qatar
 Israel
 Rest of Middle East
o Africa
 South Africa
 Egypt
 Morocco
 Rest of Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances